ALPN
Price
$64.56
Change
-$0.06 (-0.09%)
Updated
Apr 26, 6:59 PM EST
13 days until earnings call
RYTM
Price
$38.28
Change
+$0.13 (+0.34%)
Updated
Apr 26, 6:59 PM EST
4 days until earnings call
Ad is loading...

ALPN vs RYTM ᐉ Comparison: Which is Better to Invest?

Header iconALPN vs RYTM Comparison
Open Charts ALPN vs RYTMBanner chart's image
Alpine Immune Sciences
Price$64.56
Change-$0.06 (-0.09%)
Volume$631.15K
CapitalizationN/A
Rhythm Pharmaceuticals
Price$38.28
Change+$0.13 (+0.34%)
Volume$173.33K
CapitalizationN/A
View a ticker or compare two or three
ALPN vs RYTM Comparison Chart

Loading...

ALPNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RYTMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ALPN vs. RYTM commentary
Apr 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALPN is a Hold and RYTM is a StrongSell.

COMPARISON
Comparison
Apr 27, 2024
Stock price -- (ALPN: $64.62 vs. RYTM: $38.15)
Brand notoriety: ALPN and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALPN: 70% vs. RYTM: 77%
Market capitalization -- ALPN: $4.24B vs. RYTM: $2.29B
ALPN [@Biotechnology] is valued at $4.24B. RYTM’s [@Biotechnology] market capitalization is $2.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $562.44B to $0. The average market capitalization across the [@Biotechnology] industry is $2.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALPN’s FA Score shows that 1 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • ALPN’s FA Score: 1 green, 4 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, ALPN is a better buy in the long-term than RYTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALPN’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 2 bullish TA indicator(s).

  • ALPN’s TA Score: 4 bullish, 4 bearish.
  • RYTM’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ALPN is a better buy in the short-term than RYTM.

Price Growth

ALPN (@Biotechnology) experienced а +0.29% price change this week, while RYTM (@Biotechnology) price change was +0.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.51%. For the same industry, the average monthly price growth was -3.37%, and the average quarterly price growth was +1265.61%.

Reported Earning Dates

ALPN is expected to report earnings on Aug 13, 2024.

RYTM is expected to report earnings on Jul 30, 2024.

Industries' Descriptions

@Biotechnology (+7.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ALPN with price predictions.
OPEN
A.I.dvisor published
a Summary for RYTM with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ALPN($4.24B) has a higher market cap than RYTM($2.29B). ALPN YTD gains are higher at: 239.035 vs. RYTM (-17.011).
ALPNRYTMALPN / RYTM
Capitalization4.24B2.29B185%
EBITDAN/AN/A-
Gain YTD239.035-17.011-1,405%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ALPN vs RYTM: Fundamental Ratings
ALPN
RYTM
OUTLOOK RATING
1..100
2863
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
267
SMR RATING
1..100
9398
PRICE GROWTH RATING
1..100
3441
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALPN's Valuation (73) in the Biotechnology industry is in the same range as RYTM (73). This means that ALPN’s stock grew similarly to RYTM’s over the last 12 months.

ALPN's Profit vs Risk Rating (2) in the Biotechnology industry is somewhat better than the same rating for RYTM (67). This means that ALPN’s stock grew somewhat faster than RYTM’s over the last 12 months.

ALPN's SMR Rating (93) in the Biotechnology industry is in the same range as RYTM (98). This means that ALPN’s stock grew similarly to RYTM’s over the last 12 months.

ALPN's Price Growth Rating (34) in the Biotechnology industry is in the same range as RYTM (41). This means that ALPN’s stock grew similarly to RYTM’s over the last 12 months.

ALPN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RYTM (100). This means that ALPN’s stock grew similarly to RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALPNRYTM
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
ALPNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RYTMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QID49.230.52
+1.07%
ProShares UltraShort QQQ
SUPL38.680.19
+0.50%
ProShares Supply Chain Logistics ETF
HDEF24.500.09
+0.37%
Xtrackers MSCI EAFE High Div Yld Eq ETF
BKEM57.040.10
+0.17%
BNY Mellon Emerging Markets Equity ETF
XFIX50.52-0.07
-0.15%
F/m Opportunistic Income ETF

ALPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPN has been loosely correlated with AXON. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPN jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPN
1D Price
Change %
ALPN100%
+0.08%
AXON - ALPN
39%
Loosely correlated
+1.27%
VERA - ALPN
37%
Loosely correlated
-3.15%
ACLX - ALPN
35%
Loosely correlated
-2.73%
AURA - ALPN
34%
Loosely correlated
-0.28%
KOD - ALPN
34%
Loosely correlated
-5.77%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with FOLD. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then FOLD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-3.93%
FOLD - RYTM
36%
Loosely correlated
-3.51%
KURA - RYTM
34%
Loosely correlated
+1.33%
KALV - RYTM
33%
Loosely correlated
+1.35%
VCYT - RYTM
33%
Poorly correlated
-2.11%
GOSS - RYTM
33%
Poorly correlated
-5.41%
More